21 May 2015 
EMA/CHMP/324747/2015  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Kuvan 
sapropterin 
On 21 May 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Kuvan. 
The marketing authorisation holder for this medicinal product is Merck Serono Europe Limited. 
The CHMP adopted an extension to an existing indication as follows2:  
“Kuvan is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients 
of all ages4 years of age and over with phenylketonuria (PKU) who have been shown to be responsive to 
such treatment (see section 4.2).” 
For information, the full indication for Kuvan will be as follows: 
“Kuvan is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients 
of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment (see 
section 4.2). 
Kuvan is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric 
patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to 
such treatment (see section 4.2).” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
                                                
